- Home
- FCFS vs LEGN Comparison
FCFS vs LEGN Comparison
Compare FCFS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- LEGN
- Stock Information
- Founded
- FCFS 1988
- LEGN 2014
- Country
- FCFS United States
- LEGN United States
- Employees
- FCFS N/A
- LEGN N/A
- Industry
- FCFS Other Specialty Stores
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- LEGN Health Care
- Exchange
- FCFS Nasdaq
- LEGN Nasdaq
- Market Cap
- FCFS 5.9B
- LEGN 7.0B
- IPO Year
- FCFS 1991
- LEGN 2020
- Fundamental
- Price
- FCFS $132.75
- LEGN $31.78
- Analyst Decision
- FCFS Buy
- LEGN Strong Buy
- Analyst Count
- FCFS 3
- LEGN 13
- Target Price
- FCFS $133.50
- LEGN $79.42
- AVG Volume (30 Days)
- FCFS 388.5K
- LEGN 1.5M
- Earning Date
- FCFS 04-24-2025
- LEGN 05-13-2025
- Dividend Yield
- FCFS 1.15%
- LEGN N/A
- EPS Growth
- FCFS 21.73
- LEGN N/A
- EPS
- FCFS 6.25
- LEGN N/A
- Revenue
- FCFS $3,388,567,000.00
- LEGN $627,241,000.00
- Revenue This Year
- FCFS $2.49
- LEGN $65.96
- Revenue Next Year
- FCFS $5.50
- LEGN $52.55
- P/E Ratio
- FCFS $21.25
- LEGN N/A
- Revenue Growth
- FCFS 5.06
- LEGN 119.97
- 52 Week Low
- FCFS $100.24
- LEGN $29.27
- 52 Week High
- FCFS $135.57
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- FCFS 63.38
- LEGN 41.49
- Support Level
- FCFS $132.99
- LEGN $30.25
- Resistance Level
- FCFS $135.57
- LEGN $35.81
- Average True Range (ATR)
- FCFS 2.81
- LEGN 1.45
- MACD
- FCFS 0.12
- LEGN -0.18
- Stochastic Oscillator
- FCFS 82.98
- LEGN 27.58
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.